Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
The Swiss pharmaceutical chemicals firm Lonza plans to invest $15 million to expand antibody-drug conjugate (ADC) production capacity in Visp, Switzerland. Lonza calls itself a pioneer in the manufacturing of ADCs, which are now being tested against cancer in dozens of clinical trials. The firm says the project will double large-scale ADC capacity at the site when it is completed in the second quarter of 2014.
This article has been sent to the following recipient: